Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Get access
Powerful Medical
•
10. January 2025
•
2 min to read
  • Case Report

The Crucial Role of Image Quality in AI-enabled ECG Digitization and Interpretation of Occlusion Myocardial Infarction

Link to Publication

Overview:

The effectiveness of AI-ECG tools depends on the quality of input data—poor ECG image quality can lead to critical misdiagnoses. This case shows how a low-quality scan triggered a false STEMI alert, later corrected with improved digitization. It underscores the importance of ensuring minimally acceptable image quality, as even advanced tools can’t fully correct severe distortions.

Published In: Journal of Electrocardiology

Date of Publication: January 10, 2025

Highlights

  • Acceptable digitization of ECG images requires a minimal quality of input
  • Contemporary digitization by the PMcardio digitization software can correct many, but not all, distortions and deletions
  • Proportionality between QRS and ST/T is crucial; truncation of any part of the QRS or ST/T distorts these proportions.


Authors: Robert Herman, MD, PhD; Stephen W. Smith, MD

Link to Publication
Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

All Publications
  • Case Report
  • Cureus
  • November 26, 2025

Bifascicular Block Associated With Myocardial Infarction: A Marker of Proximal Left Anterior Descending Artery Occlusion Confirmed by the Artificial Intelligence-Based Smartphone App Queen of Hearts

This single-patient case report describes an elderly man presenting with chest pain, hypotension, and bifascicular block (BFB)—a combination of right bundle branch block (RBBB) and left anterior fascicular block (LAFB)—whose ECG showed QRS‑concordant anterior and lateral ST‑segment elevation consistent with a STEMI‑equivalent / occlusive myocardial infarction (OMI) pattern. Urgent coronary angiography revealed a long, severely calcified, near‑occlusive proximal left anterior descending (LAD) artery lesion, successfully treated with primary PCI and drug‑eluting stent implantation, achieving TIMI 3 flow. The Queen of Hearts (PMcardio) AI‑based smartphone app correctly classified the ECG as STEMI‑equivalent, identified atrial flutter and BFB, and predicted reduced left ventricular ejection fraction, later confirmed by echocardiography (EF 38%). This case underscores BFB with concordant anterior ST elevation as a high‑risk marker of proximal LAD‑culprit OMI and provides anecdotal evidence that specialized AI‑enabled ECG interpretation can support rapid, accurate decision‑making in ACS. 
  • Study
  • Resuscitation
  • November 19, 2025

Artificial Intelligence Versus Human Expertise: ECG-Based Detection of Occlusive Myocardial Infarction After Cardiac Arrest

This single-centre study tested whether AI-based ECG analysis can detect occlusive myocardial infarction (OMI) after cardiac arrest using post-ROSC ECGs from 97 patients with subsequent coronary angiography. A dedicated deep neural network (Queen of Hearts, QoH) achieved the highest discrimination for acute coronary occlusion (AUC 0.85) and OMI (AUC 0.75), outperforming human experts, with a more balanced trade-off between sensitivity and specificity. In contrast, two large language model–based chatbots (ChatGPT and a GPT-based EKG Analyst) showed near-perfect sensitivity but almost no specificity, labelling nearly all ECGs as OMI and thus providing no meaningful diagnostic discrimination. These findings suggest that specialized ECG-trained AI, such as QoH, may serve as a useful adjunct in post-resuscitation decision-making. In contrast, general-purpose LLMs are currently unsuitable for critical ECG diagnosis.
More articles

Join over 100,000 healthcare professionals who are already taking advantage of AI

Download PMcardio app on the Apple App Store
Get PMcardio app on Google Play Store

Ready to get started?

Get access

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s certified PMcardio platform revolutionizes the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

Logo of Next Gen EU
Logo of Next Gen EU
MedTech Innovator 2025 Finalist badge in white.

Products

Company

Resources

Legal

Envelope Linkedin-in Instagram Facebook-f

© Powerful Medical 2025

Privacy

&

Cookies

Legal

Powerful Medical, Inc. | PMcardio and the PMcardio logo are registered trademarks of Powerful Medical. Additionally, Queen of Hearts is claimed as a trademark of Powerful Medical.

 

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Get access